As of today (2024-04-29), icad's share price is $1.47.
icad's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.24. Hence, icad's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for icad's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, icad's highest Price-to-Free-Cash-Flow Ratio was 321.43. The lowest was 12.02. And the median was 39.40.
ICAD's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 31.59 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 10.30% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -2.40% per year.
During the past 13 years, icad's highest 3-Year average Free Cash Flow per Share Growth Rate was 62.30% per year. The lowest was -130.90% per year. And the median was 6.70% per year.
icad Price-to-Free-Cash-Flow Historical Data
The historical data trend for icad's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of icad's Price-to-Free-Cash-Flow
For the Medical Devices subindustry, icad's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
icad's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, icad's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where icad's Price-to-Free-Cash-Flow falls into.
icad Price-to-Free-Cash-Flow Calculation
icad's Price-to-Free-Cash-Flow ratio for today is calculated as
icad's Share Price of today is $1.47. icad's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
icad Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of icad's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ICAD has been successfully added to your 